


Figure S10



Supplementary Figure S10.

A, Quantification of G-CSF and CXCL1 in day 20 tumor lysates following indicated *in vivo* treatments, n=3-4 mice from one experiment. P values by one-tailed Mann-Whitney test. **B**, Quantification of neutrophils in LLC tumors treated with indicated antibodies and harvested at day 13, from one experiment with n=5 mice. P value by one-tailed t test. **C**, Growth curves for individual mice shown in **Fig. 4A**. **D**, Growth curves for individual mice shown in **Fig. 4C**. **E and F**, Quantification of mean volumes and area under curve (AUC) for LLC MSI-H tumors implanted into wild type vs. *Csf3r*^{-/-} G-CSF Receptor knockout mice. n=5-7 mice per condition from one experiment. Two-tailed adjusted p value by t test. **G**, Individual growth curves for mice in experiment shown in **(E)**. **H**, Quantification of neutrophils as percent of singlets in tumor from day 20 LLC MSI-H tumors treated with ICIs and implanted into wild type vs. *Csf3r*^{-/-} mice. n=5-6 per condition from one experiment. P value by two-tailed t test. **I and J**, Quantification of mean volumes and AUC for LLC MSI-H tumors with or without G-CSF neutralizing antibody treatment (aGCSF). n=5 from one representative *in vivo* experiment from three independent experiments. P value by two-tailed t test. **K**, Quantification of F4/80+ tumor-associated macrophages (TAMs) from day 20 LLC MSI-H tumors treated with or without IL1R1 neutralizing antibody. n=5 mice from one experiment. p value by two-tailed t test. **L**, Quantification of CD31+ endothelial cells as for **(K)**. **M**, Quantification of mean marker intensity for indicated markers for F4/80+ TAMs in LLC MSI-H ICI treated tumors with or without aIL1R1 treatment. n=5 mice from one experiment. P value by two-tailed t tests. For all applicable panels, error bars represent mean +/- SD.